Follow-Up Study of Kidney Cancer Patients
Summary
Background:
In Central Europe, mortality rates for kidney cancers are higher and survival rates are lower than in the United States and Western Europe overall.
The Central and Eastern European Renal Cancer Case-Control Study (CEERCC), completed in 2002, offers an opportunity to identify determinants that predict 5-year survival among kidney cancer patients.
Objectives:
To assess disease recurrence and progression among former participants in the CEERCC.
To investigate the effect of genetics, lifestyle factors, medical conditions, occupation and diet on the outcome of kidney cancer patients in Europe.
Eligibility:
Former participants or next-of-kin of former participants in the CEERCC study.
Design:
Participants or their next-of-kin are interviewed for 60 minutes and are requested permission to collect relevant information from their or their family member's hospital and cancer registry records.
Description
We propose to conduct a follow-up study of kidney cancer in the high risk region of Central and Eastern Europe. This study would be conducted through the follow-up of a group of patients with kidney cancer that were previously enrolled in the study entitled Occupation, Genetic Susceptibility Kidney Cancer: Central European Case-Control Study, PI Dr. Wong-Ho Chow, OEEB, DCEG, NCI, protocol No. 01-C-N063, a study which is currently out of the field and for which data analyses of the main study are complete. Like the case-control study, the follow-up study would be conducted in six countries, including Romania, Hungary, Poland, Russia, and the Czech Republic. In each study center, cancer-related information will be extracted from vital statistics, cancer registry, and/or medical records to be linked with the previous patient series. If they agree, or if their next-of-kin agrees under the circumstance that the patients are deceased, they or their next-of-kin will also be interviewed with a brief questionnaire. The overall aim is to investigate the role of established and potential determinants of survival by abstracting information from vital statistics, cancer registries, and medical records and by interviewing participating cancer cases or their next-of-kin when possible. We also plan to investigate the role of genetic factors that we hypothesize will affect prognosis and survival among these patients.
First, we will conduct a pilot study to determine the feasibility of collecting survival information including 5-year survival status, date of death, cause of death, and date of last follow-up if alive on 220 cases from the six collaborating centers. Information on 50 cases will be obtained from Olomouc and Moscow and 30 cases from the remaining centers (Bucharest, Prague, Brno, Lodz), using a list of cases provided by the NCI. The feasibility of abstracting additional information including surgical and medical treatment procedures used to treat primary disease, recurrence and progression of primary disease will also be determined. Abstracted information collected and translated into English, in addition to a report describing any obstacles to obtaining information requested will be provided by IARC to the NCI. If we can obtain information from 80% of cases in the feasibility study, we will proceed with the full survival study. The objectives of the main study are: (1) to assess the 5-year survival status of kidney cancer patients in the CEERCC study; (2) to assess prevalence of recurrent disease and progression; (3) to investigate additional patient-, tumor- and genetic determinants of 5-years survival in cases.
Study Design
N/A
Conditions
Kidney Cancer
Location
International Agency for Research on Cancer
Lyon
France
Status
Recruiting
Source
National Institutes of Health Clinical Center (CC)
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00656955
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Kidney Papillary Necrosis
A complication of kidney diseases characterized by cell death involving KIDNEY PAPILLA in the KIDNEY MEDULLA. Damages to this area may hinder the kidney to concentrate urine resulting in POLYURIA. Sloughed off necrotic tissue may block KIDNEY PELVIS or URETER. Necrosis of multiple renal papillae can lead to KIDNEY FAILURE.
Kidney Cortex
The outer zone of the KIDNEY, beneath the capsule, consisting of KIDNEY GLOMERULUS; KIDNEY TUBULES, DISTAL; and KIDNEY TUBULES, PROXIMAL.
Kidney Tubules
Long convoluted tubules in the nephrons. They collect filtrate from blood passing through the KIDNEY GLOMERULUS and process this filtrate into URINE. Each renal tubule consists of a BOWMAN CAPSULE; PROXIMAL KIDNEY TUBULE; LOOP OF HENLE; DISTAL KIDNEY TUBULE; and KIDNEY COLLECTING DUCT leading to the central cavity of the kidney (KIDNEY PELVIS) that connects to the URETER.
Kidney Calculi
Stones in the KIDNEY, usually formed in the urine-collecting area of the kidney (KIDNEY PELVIS). Their sizes vary and most contains CALCIUM OXALATE.
Hydronephrosis
Abnormal enlargement or swelling of a KIDNEY due to dilation of the KIDNEY CALICES and the KIDNEY PELVIS. It is often associated with obstruction of the URETER or chronic kidney diseases that prevents normal drainage of urine into the URINARY BLADDER.
Clinical Trials
Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer
RATIONALE: Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of carboxyamidotriazole in tre...
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. It is not yet known which regimen of interleukin-2 is most effective for kidney cancer. PURPOSE:...
RPI.4610 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: RPI.4610 may stop the growth of metastatic kidney cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of RPI.4610 in treating patient...
Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer cells. PURPOSE: Phase IV trial to study the effectiveness of interleukin-2 in treating patients w...
Interferon Alfa With or Without Isotretinoin in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Interferon alfa may interfere with the growth of the cancer cells and slow the growth of kidney cancer. Isotretinoin may help kidney cancer cells develop into normal cells. It i...
PubMed Articles
Kidney cancer: Assessing the management of localized kidney cancer.
Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies.
AIMS/HYPOTHESIS: Diabetes is associated with increased risk of cancer at several sites, but its association with cancer of the kidney is unclear. We performed a systematic review with meta-analysis to...
Incidence of cancer in kidney-transplant recipients: A long-term cohort study in a single center.
In a long-term cohort study, we calculated cancer incidences and survival rates after the development of these cancers in kidney-transplant recipients. The cancer incidences were compared with those i...
Clinical features of kidney cancer in primary care: a case-control study using primary care records.
Kidney cancer accounts for over 4000 UK deaths annually, and is one of the cancer sites with a poor mortality record compared with Europe.
Mortality in Vermont granite workers and its association with silica exposure.
Objectives To assess mortality in Vermont granite workers and examine relationships between silica exposure and mortality from lung cancer, kidney cancer, non-malignant kidney disease, silicosis and o...
